PL

Peter F. Lebowitz

GL Glaxosmithkline: 4 patents #75 of 646Top 15%
NA Novartis Ag: 2 patents #1,923 of 5,128Top 40%
Overall (All Time): #832,943 of 4,157,543Top 25%
6
Patents All Time

Issued Patents All Time

Patent #TitleCo-InventorsDate
10869869 Method of adjuvant cancer treatment Sylvie Laquerre 2020-12-22
9402846 Combination of inhibitor of B-Raf and inhibitor of AKT in the treatment of cancer Melissa Dumble, Tona Gilmer, Rakesh Kumar, Sylvie Laquerre, Shannon Renae Morris 2016-08-02
8952018 Pharmaceutical combination of MEK inhibitor and B-Raf inhibitors Melissa Dumble, Rakesh Kumar, Sylvie Laquerre 2015-02-10
8835450 Combination of inhibitor of B-Raf and an inhibitor of Akt in the treatment of cancer Melissa Dumble, Tona Gilmer, Rakesh Kumar, Shannon Renae Morris, Sylvie Laquerre 2014-09-16
8796298 Combination of a B-Raf inhibitor: N-{3-[5-(2-Amino-4-pyrimidinyl)-2-(1,1- dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide and the Akt inhibitor: N-{ (1S)-2-amino-1-[(3- fluorophenyl)methyl]ethyl}-5-chIoro-4-(4-chIoro- 1 -methyl- 1 H-pyrazol-5-yl)-2-10 thiophenecarboxamide useful in the treatment of cancer Melissa Dumble, Tona Gilmer, Rakesh Kumar, Shannon Renae Morris, Sylvie Laquerre 2014-08-05
8703781 Pharmaceutical combination of MEK inhibitor and B-RAF inhibitors Melissa Dumble, Rakesh Kumar, Sylvie Laquerre 2014-04-22